Toggle navigation
- Valbiotis announces the first visit of the first patientin the TOTUM•63 mode of action clinical study conducted by the INAF1, in partnership with Nestlé Health Science
Voir le communiqué de presse
- Signing of a Term Sheet for €100 million in syndicated financing to support the Group’s growth (IN FRENCH).
Voir le communiqué de presse
- How can and should health and climate-conscious agricultural approaches create value in our territories ? (IN FRENCH).
Voir le communiqué de presse
- 2021 annual results
Voir le communiqué de presse
- Valbiotis announces the positive results of its clinical study on the bioavailability and mode of action of TOTUM•070,against hypercholesterolemia.
Voir le communiqué de presse
- Valbiotis is strengthening its commitment to CSR by joining the United Nations Global Compact and applying the ISO 26000 standard
Voir le communiqué de presse
- Carbios takes textile circularity a step further with its enzymatic recycling technology
Voir le communiqué de presse
- Valbiotis announces upcoming organizational changes of its Board of Directors.
Voir le communiqué de presse
- Valbiotis presents its 2022 financial communication calendar
Voir le communiqué de presse
- Valbiotis announces approval to launch the two Phase II/III INSIGHT and INSIGHT 2 clinical studies, the last step in the development of TOTUM•854 for the reduction of blood pressure.
Voir le communiqué de presse
